BRPI0720441A2 - Indóis que atuam como antagonistas de receptor v1a - Google Patents

Indóis que atuam como antagonistas de receptor v1a Download PDF

Info

Publication number: BRPI0720441A2
Authority: BR; Brazil
Prior art keywords: halo; alkyl; alkoxy; formula; hydrogen
Prior art date: 2006-12-08

Application number

BRPI0720441-8A

Other languages

English (en)

Portuguese (pt)

Inventor

Caterina Bissantz

Christophe Grundschober

Raffaello Masciadri

Hasane Ratni

Mark Rogers-Evans

Patrick Schnider

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-12-08

Filing date

2007-11-29

Publication date

2014-01-07

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38983746&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0720441(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-11-29 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2014-01-07 Publication of BRPI0720441A2 publication Critical patent/BRPI0720441A2/pt

Links

239000005557 antagonist Substances 0.000 title description 3
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 147
239000001257 hydrogen Substances 0.000 claims description 99
229910052739 hydrogen Inorganic materials 0.000 claims description 99
-1 halo C1-6 alkoxy Chemical group 0.000 claims description 98
239000002253 acid Substances 0.000 claims description 70
125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 69
238000000034 method Methods 0.000 claims description 65
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 65
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 62
150000001875 compounds Chemical class 0.000 claims description 61
125000000217 alkyl group Chemical group 0.000 claims description 58
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 53
125000004093 cyano group Chemical group *C#N 0.000 claims description 52
125000003545 alkoxy group Chemical group 0.000 claims description 47
125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 37
229910052757 nitrogen Inorganic materials 0.000 claims description 36
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 32
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 24
229910052760 oxygen Inorganic materials 0.000 claims description 22
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 19
125000005605 benzo group Chemical group 0.000 claims description 18
229960003726 vasopressin Drugs 0.000 claims description 18
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 claims description 17
108010004977 Vasopressins Proteins 0.000 claims description 17
102000002852 Vasopressins Human genes 0.000 claims description 17
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 claims description 16
125000005842 heteroatom Chemical group 0.000 claims description 15
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 14
239000001301 oxygen Substances 0.000 claims description 14
125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 13
125000004354 sulfur functional group Chemical group 0.000 claims description 12
208000019901 Anxiety disease Diseases 0.000 claims description 11
230000036506 anxiety Effects 0.000 claims description 11
125000000592 heterocycloalkyl group Chemical group 0.000 claims description 11
125000002947 alkylene group Chemical group 0.000 claims description 10
208000020401 Depressive disease Diseases 0.000 claims description 9
150000003839 salts Chemical class 0.000 claims description 9
125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 8
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 7
206010007558 Cardiac failure chronic Diseases 0.000 claims description 7
208000005171 Dysmenorrhea Diseases 0.000 claims description 7
206010013935 Dysmenorrhoea Diseases 0.000 claims description 7
206010020772 Hypertension Diseases 0.000 claims description 7
206010029164 Nephrotic syndrome Diseases 0.000 claims description 7
208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 7
208000019425 cirrhosis of liver Diseases 0.000 claims description 7
230000028327 secretion Effects 0.000 claims description 7
229910052727 yttrium Inorganic materials 0.000 claims description 7
238000006243 chemical reaction Methods 0.000 claims description 6
239000003814 drug Substances 0.000 claims description 6
239000008194 pharmaceutical composition Substances 0.000 claims description 6
XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 claims description 6
125000000753 cycloalkyl group Chemical group 0.000 claims description 5
229910003827 NRaRb Inorganic materials 0.000 claims description 4
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
125000004494 ethyl ester group Chemical group 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
238000002360 preparation method Methods 0.000 claims description 4
UZRNMSVNFCFTSX-UHFFFAOYSA-N 2-[5-chloro-2-[4-(2-oxo-3h-benzimidazol-1-yl)piperidine-1-carbonyl]-1h-indol-7-yl]acetonitrile Chemical compound C12=CC=CC=C2NC(=O)N1C(CC1)CCN1C(=O)C1=CC2=CC(Cl)=CC(CC#N)=C2N1 UZRNMSVNFCFTSX-UHFFFAOYSA-N 0.000 claims description 3
XJCJWQCYZCPKNB-UHFFFAOYSA-N 2-[5-chloro-2-[4-(2-oxo-3h-benzimidazol-1-yl)piperidine-1-carbonyl]indol-1-yl]acetonitrile Chemical compound C12=CC=CC=C2NC(=O)N1C(CC1)CCN1C(=O)C1=CC2=CC(Cl)=CC=C2N1CC#N XJCJWQCYZCPKNB-UHFFFAOYSA-N 0.000 claims description 3
150000001412 amines Chemical class 0.000 claims description 3
239000012039 electrophile Substances 0.000 claims description 3
DJLSZQZOXVHFPB-UHFFFAOYSA-N 2-[5-bromo-2-[4-(2-oxo-3h-benzimidazol-1-yl)piperidine-1-carbonyl]indol-1-yl]acetonitrile Chemical compound C12=CC=CC=C2NC(=O)N1C(CC1)CCN1C(=O)C1=CC2=CC(Br)=CC=C2N1CC#N DJLSZQZOXVHFPB-UHFFFAOYSA-N 0.000 claims description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
QFDCRKBTPMOEDE-UHFFFAOYSA-N n-[5-methoxy-2-[4-(2-oxo-3h-benzimidazol-1-yl)piperidine-1-carbonyl]-1h-indol-3-yl]-2-nitrobenzamide Chemical compound C12=CC(OC)=CC=C2NC(C(=O)N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)=C1NC(=O)C1=CC=CC=C1[N+]([O-])=O QFDCRKBTPMOEDE-UHFFFAOYSA-N 0.000 claims description 2
230000002265 prevention Effects 0.000 claims description 2
125000001475 halogen functional group Chemical group 0.000 claims 26
150000002431 hydrogen Chemical group 0.000 claims 18
JYJLUJUISXAZAF-UHFFFAOYSA-N (5-chloro-1h-indol-2-yl)-piperidin-1-ylmethanone Chemical compound C=1C2=CC(Cl)=CC=C2NC=1C(=O)N1CCCCC1 JYJLUJUISXAZAF-UHFFFAOYSA-N 0.000 claims 1
YKLKFBYKBNSWIB-UHFFFAOYSA-N 1-[1-(5-chloro-1h-indole-2-carbonyl)piperidin-4-yl]-3h-indol-2-one Chemical compound O=C1CC2=CC=CC=C2N1C(CC1)CCN1C(=O)C1=CC2=CC(Cl)=CC=C2N1 YKLKFBYKBNSWIB-UHFFFAOYSA-N 0.000 claims 1
125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 1
208000035475 disorder Diseases 0.000 claims 1
125000005843 halogen group Chemical group 0.000 description 76
230000008878 coupling Effects 0.000 description 53
238000010168 coupling process Methods 0.000 description 53
238000005859 coupling reaction Methods 0.000 description 53
238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 52
150000001408 amides Chemical class 0.000 description 51
BYNBAMHAURJNTR-UHFFFAOYSA-N 3-piperidin-4-yl-1h-benzimidazol-2-one Chemical compound O=C1NC2=CC=CC=C2N1C1CCNCC1 BYNBAMHAURJNTR-UHFFFAOYSA-N 0.000 description 46
HCUARRIEZVDMPT-UHFFFAOYSA-N Indole-2-carboxylic acid Chemical compound C1=CC=C2NC(C(=O)O)=CC2=C1 HCUARRIEZVDMPT-UHFFFAOYSA-N 0.000 description 26
239000000460 chlorine Substances 0.000 description 20
239000000243 solution Substances 0.000 description 20
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 16
239000000203 mixture Substances 0.000 description 15
102000005962 receptors Human genes 0.000 description 12
108020003175 receptors Proteins 0.000 description 12
239000011541 reaction mixture Substances 0.000 description 11
239000007787 solid Substances 0.000 description 10
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 9
125000001424 substituent group Chemical group 0.000 description 9
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 8
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 8
229910052731 fluorine Inorganic materials 0.000 description 8
239000003826 tablet Substances 0.000 description 8
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 7
235000019439 ethyl acetate Nutrition 0.000 description 7
239000011737 fluorine Substances 0.000 description 7
239000000829 suppository Substances 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
125000004432 carbon atom Chemical group C* 0.000 description 6
229910052801 chlorine Inorganic materials 0.000 description 6
239000012074 organic phase Substances 0.000 description 6
239000000546 pharmaceutical excipient Substances 0.000 description 6
239000000047 product Substances 0.000 description 6
239000011734 sodium Substances 0.000 description 6
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
239000013543 active substance Substances 0.000 description 5
210000004556 brain Anatomy 0.000 description 5
229910052794 bromium Inorganic materials 0.000 description 5
238000003818 flash chromatography Methods 0.000 description 5
239000007903 gelatin capsule Substances 0.000 description 5
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
229920006395 saturated elastomer Polymers 0.000 description 5
125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 4
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
241000700159 Rattus Species 0.000 description 4
102000004136 Vasopressin Receptors Human genes 0.000 description 4
108090000643 Vasopressin Receptors Proteins 0.000 description 4
230000027455 binding Effects 0.000 description 4
125000000623 heterocyclic group Chemical group 0.000 description 4
239000008101 lactose Substances 0.000 description 4
229920005862 polyol Polymers 0.000 description 4
150000003077 polyols Chemical class 0.000 description 4
238000002953 preparative HPLC Methods 0.000 description 4
125000004001 thioalkyl group Chemical group 0.000 description 4
125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 3
PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 3
SWEOCNYZDCMOTF-UHFFFAOYSA-N 1-o-tert-butyl 2-o-ethyl 7-(bromomethyl)-5-chloroindole-1,2-dicarboxylate Chemical compound ClC1=CC(CBr)=C2N(C(=O)OC(C)(C)C)C(C(=O)OCC)=CC2=C1 SWEOCNYZDCMOTF-UHFFFAOYSA-N 0.000 description 3
FUQOTYRCMBZFOL-UHFFFAOYSA-N 5-chloro-1H-indole-2-carboxylic acid Chemical compound ClC1=CC=C2NC(C(=O)O)=CC2=C1 FUQOTYRCMBZFOL-UHFFFAOYSA-N 0.000 description 3
PLCUFDCXTCLQHR-UHFFFAOYSA-N 5-chloro-7-(cyanomethyl)-1h-indole-2-carboxylic acid Chemical compound ClC1=CC(CC#N)=C2NC(C(=O)O)=CC2=C1 PLCUFDCXTCLQHR-UHFFFAOYSA-N 0.000 description 3
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 description 3
229920002261 Corn starch Polymers 0.000 description 3
229910004298 SiO 2 Inorganic materials 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
125000003342 alkenyl group Chemical group 0.000 description 3
210000004727 amygdala Anatomy 0.000 description 3
230000006399 behavior Effects 0.000 description 3
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
239000002775 capsule Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000012043 crude product Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
125000001072 heteroaryl group Chemical group 0.000 description 3
OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000003921 oil Substances 0.000 description 3
235000019198 oils Nutrition 0.000 description 3
239000000825 pharmaceutical preparation Substances 0.000 description 3
239000002464 receptor antagonist Substances 0.000 description 3
229940044551 receptor antagonist Drugs 0.000 description 3
229930195734 saturated hydrocarbon Natural products 0.000 description 3
239000000454 talc Substances 0.000 description 3
229910052623 talc Inorganic materials 0.000 description 3
239000001993 wax Substances 0.000 description 3
125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 2
SLQUFVJVTDUONL-UHFFFAOYSA-N 1-(cyanomethyl)indole-2-carboxylic acid Chemical compound C1=CC=C2N(CC#N)C(C(=O)O)=CC2=C1 SLQUFVJVTDUONL-UHFFFAOYSA-N 0.000 description 2
JIJSINNUUYUAFQ-UHFFFAOYSA-N 1-o-tert-butyl 2-o-ethyl 5-chloro-7-(cyanomethyl)indole-1,2-dicarboxylate Chemical compound ClC1=CC(CC#N)=C2N(C(=O)OC(C)(C)C)C(C(=O)OCC)=CC2=C1 JIJSINNUUYUAFQ-UHFFFAOYSA-N 0.000 description 2
GSIHDRYDPOMJHM-UHFFFAOYSA-N 3-[1-(7-phenylmethoxy-1h-indole-2-carbonyl)piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1CC(N2C(NC3=CC=CC=C32)=O)CCN1C(=O)C(NC1=2)=CC1=CC=CC=2OCC1=CC=CC=C1 GSIHDRYDPOMJHM-UHFFFAOYSA-N 0.000 description 2
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
239000004215 Carbon black (E152) Substances 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
101150026303 HEX1 gene Proteins 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000029936 alkylation Effects 0.000 description 2
238000005804 alkylation reaction Methods 0.000 description 2
125000004429 atom Chemical group 0.000 description 2
239000011324 bead Substances 0.000 description 2
239000012148 binding buffer Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
229940099112 cornstarch Drugs 0.000 description 2
239000008298 dragée Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
230000002526 effect on cardiovascular system Effects 0.000 description 2
CVVUNXTUIODJMM-UHFFFAOYSA-N ethyl 5-chloro-7-(cyanomethyl)-1h-indole-2-carboxylate Chemical compound ClC1=CC(CC#N)=C2NC(C(=O)OCC)=CC2=C1 CVVUNXTUIODJMM-UHFFFAOYSA-N 0.000 description 2
SJRZGOYZIYIJQZ-UHFFFAOYSA-N ethyl 5-chloro-7-methyl-1h-indole-2-carboxylate Chemical compound ClC1=CC(C)=C2NC(C(=O)OCC)=CC2=C1 SJRZGOYZIYIJQZ-UHFFFAOYSA-N 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
239000013604 expression vector Substances 0.000 description 2
239000003925 fat Substances 0.000 description 2
229930195733 hydrocarbon Natural products 0.000 description 2
125000001183 hydrocarbyl group Chemical group 0.000 description 2
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
QNLOWBMKUIXCOW-UHFFFAOYSA-N indol-2-one Chemical compound C1=CC=CC2=NC(=O)C=C21 QNLOWBMKUIXCOW-UHFFFAOYSA-N 0.000 description 2
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
238000011813 knockout mouse model Methods 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
239000012139 lysis buffer Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000000463 material Substances 0.000 description 2
239000012528 membrane Substances 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
WEVYAHXRMPXWCK-UHFFFAOYSA-N methyl cyanide Natural products CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
230000009871 nonspecific binding Effects 0.000 description 2
239000008188 pellet Substances 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
150000003254 radicals Chemical class 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
238000007127 saponification reaction Methods 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
229910052717 sulfur Chemical group 0.000 description 2
239000011593 sulfur Chemical group 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
238000012360 testing method Methods 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
235000015112 vegetable and seed oil Nutrition 0.000 description 2
239000008158 vegetable oil Substances 0.000 description 2
JQYYDAPQCHWQCC-UHFFFAOYSA-N 1-(4-piperidinyl)-1,3-dihydro-2h-indol-2-one Chemical compound O=C1CC2=CC=CC=C2N1C1CCNCC1 JQYYDAPQCHWQCC-UHFFFAOYSA-N 0.000 description 1
YZUPZGFPHUVJKC-UHFFFAOYSA-N 1-bromo-2-methoxyethane Chemical compound COCCBr YZUPZGFPHUVJKC-UHFFFAOYSA-N 0.000 description 1
UQPQAWFLYZMNRO-UHFFFAOYSA-N 1-methoxyindole-2-carboxylic acid Chemical compound C1=CC=C2N(OC)C(C(O)=O)=CC2=C1 UQPQAWFLYZMNRO-UHFFFAOYSA-N 0.000 description 1
HDZMKEASBKFOLX-UHFFFAOYSA-N 1-o-tert-butyl 2-o-ethyl 5-chloro-7-methylindole-1,2-dicarboxylate Chemical compound ClC1=CC(C)=C2N(C(=O)OC(C)(C)C)C(C(=O)OCC)=CC2=C1 HDZMKEASBKFOLX-UHFFFAOYSA-N 0.000 description 1
SIAVYRCOEMDHCU-UHFFFAOYSA-N 1-piperidin-4-ylbenzotriazole Chemical compound C1CNCCC1N1C2=CC=CC=C2N=N1 SIAVYRCOEMDHCU-UHFFFAOYSA-N 0.000 description 1
YLNPBSVOVVEMBE-UHFFFAOYSA-N 2-[(4-chloro-2-methylphenyl)hydrazinylidene]propanoic acid Chemical compound CC(=NNc1ccc(Cl)cc1C)C(O)=O YLNPBSVOVVEMBE-UHFFFAOYSA-N 0.000 description 1
RKHVPOWVSIXGDF-UHFFFAOYSA-N 2-[2-[4-(2-oxo-3h-benzimidazol-1-yl)piperidine-1-carbonyl]indol-1-yl]acetonitrile Chemical compound C1=CC=C2N(CC#N)C(C(N3CCC(CC3)N3C(NC4=CC=CC=C43)=O)=O)=CC2=C1 RKHVPOWVSIXGDF-UHFFFAOYSA-N 0.000 description 1
RVVUOKQYUUCWKW-UHFFFAOYSA-N 2-[2-[5-methoxy-2-[4-(2-oxo-3h-benzimidazol-1-yl)piperidine-1-carbonyl]-1h-indol-3-yl]ethyl]isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1CCC1=C(C(=O)N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)NC2=CC=C(OC)C=C21 RVVUOKQYUUCWKW-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
125000004810 2-methylpropylene group Chemical group [H]C([H])([H])C([H])(C([H])([H])[*:2])C([H])([H])[*:1] 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
XFNONUNNILCXRU-UHFFFAOYSA-N 3,5,7-trimethyl-1h-indole-2-carboxylic acid Chemical compound C1=C(C)C=C2C(C)=C(C(O)=O)NC2=C1C XFNONUNNILCXRU-UHFFFAOYSA-N 0.000 description 1
PDIMPZYTLFMVNW-UHFFFAOYSA-N 3,7-dimethyl-1h-indole-2-carboxylic acid Chemical compound C1=CC=C2C(C)=C(C(O)=O)NC2=C1C PDIMPZYTLFMVNW-UHFFFAOYSA-N 0.000 description 1
JCOKHKWSBDTOOB-UHFFFAOYSA-N 3-(2-acetamidopropyl)-1h-indole-2-carboxylic acid Chemical compound C1=CC=C2C(CC(C)NC(C)=O)=C(C(O)=O)NC2=C1 JCOKHKWSBDTOOB-UHFFFAOYSA-N 0.000 description 1
KQSJKIFUOUFTQO-UHFFFAOYSA-N 3-(2-ethoxy-2-oxoethyl)-1h-indole-2-carboxylic acid Chemical compound C1=CC=C2C(CC(=O)OCC)=C(C(O)=O)NC2=C1 KQSJKIFUOUFTQO-UHFFFAOYSA-N 0.000 description 1
GCNSNDFIYNFZGA-UHFFFAOYSA-N 3-[1-(1-methylindole-2-carbonyl)piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C12=CC=CC=C2NC(=O)N1C(CC1)CCN1C(=O)C1=CC2=CC=CC=C2N1C GCNSNDFIYNFZGA-UHFFFAOYSA-N 0.000 description 1
YBVJQZRJRWMZPA-UHFFFAOYSA-N 3-[1-(3,5,7-trimethyl-1h-indole-2-carbonyl)piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C12=CC=CC=C2NC(=O)N1C(CC1)CCN1C(=O)C1=C(C)C2=CC(C)=CC(C)=C2N1 YBVJQZRJRWMZPA-UHFFFAOYSA-N 0.000 description 1
CKRYVXMTXXNJDN-UHFFFAOYSA-N 3-[1-(3,7-dimethyl-1h-indole-2-carbonyl)piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C12=CC=CC=C2NC(=O)N1C(CC1)CCN1C(=O)C1=C(C)C2=CC=CC(C)=C2N1 CKRYVXMTXXNJDN-UHFFFAOYSA-N 0.000 description 1
CNKYOMNTMQGDJV-UHFFFAOYSA-N 3-[1-(3-benzyl-5-methyl-1h-indole-2-carbonyl)piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C12=CC(C)=CC=C2NC(C(=O)N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)=C1CC1=CC=CC=C1 CNKYOMNTMQGDJV-UHFFFAOYSA-N 0.000 description 1
NAVHONKEXBKTNO-UHFFFAOYSA-N 3-[1-(3-ethyl-1h-indole-2-carbonyl)piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C12=CC=CC=C2NC(=O)N1C(CC1)CCN1C(=O)C1=C(CC)C2=CC=CC=C2N1 NAVHONKEXBKTNO-UHFFFAOYSA-N 0.000 description 1
FNQNPVUHRBLHQJ-UHFFFAOYSA-N 3-[1-(3-ethyl-4-methyl-1h-indole-2-carbonyl)piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C12=CC=CC=C2NC(=O)N1C(CC1)CCN1C(=O)C1=C(CC)C2=C(C)C=CC=C2N1 FNQNPVUHRBLHQJ-UHFFFAOYSA-N 0.000 description 1
FOMSOKIGTJHXBL-UHFFFAOYSA-N 3-[1-(3-ethyl-5-methyl-1h-indole-2-carbonyl)piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C12=CC=CC=C2NC(=O)N1C(CC1)CCN1C(=O)C1=C(CC)C2=CC(C)=CC=C2N1 FOMSOKIGTJHXBL-UHFFFAOYSA-N 0.000 description 1
HNFGBVLTKKNTPM-UHFFFAOYSA-N 3-[1-(3-phenyl-1h-indole-2-carbonyl)piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1CC(N2C(NC3=CC=CC=C32)=O)CCN1C(=O)C=1NC2=CC=CC=C2C=1C1=CC=CC=C1 HNFGBVLTKKNTPM-UHFFFAOYSA-N 0.000 description 1
SWOMGHAPRYAXFB-UHFFFAOYSA-N 3-[1-(4,5-dichloro-1h-indole-2-carbonyl)piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C12=CC=CC=C2NC(=O)N1C(CC1)CCN1C(=O)C1=CC2=C(Cl)C(Cl)=CC=C2N1 SWOMGHAPRYAXFB-UHFFFAOYSA-N 0.000 description 1
QCGDPQSAPROOAY-UHFFFAOYSA-N 3-[1-(4,5-dimethyl-1h-indole-2-carbonyl)piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C12=CC=CC=C2NC(=O)N1C(CC1)CCN1C(=O)C1=CC2=C(C)C(C)=CC=C2N1 QCGDPQSAPROOAY-UHFFFAOYSA-N 0.000 description 1
IOGUYKHBKSGHLG-UHFFFAOYSA-N 3-[1-(4,7-dimethyl-1h-indole-2-carbonyl)piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C12=CC=CC=C2NC(=O)N1C(CC1)CCN1C(=O)C(N1)=CC2=C1C(C)=CC=C2C IOGUYKHBKSGHLG-UHFFFAOYSA-N 0.000 description 1
AINVVAAZDQFWMA-UHFFFAOYSA-N 3-[1-(4-chloro-5-methoxy-1h-indole-2-carbonyl)piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C12=CC=CC=C2NC(=O)N1C(CC1)CCN1C(=O)C1=CC2=C(Cl)C(OC)=CC=C2N1 AINVVAAZDQFWMA-UHFFFAOYSA-N 0.000 description 1
SWVYSASXBQJURF-UHFFFAOYSA-N 3-[1-(4-methyl-1h-indole-2-carbonyl)piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C12=CC=CC=C2NC(=O)N1C(CC1)CCN1C(=O)C(N1)=CC2=C1C=CC=C2C SWVYSASXBQJURF-UHFFFAOYSA-N 0.000 description 1
UBLULAQAHSJALJ-UHFFFAOYSA-N 3-[1-(5,7-dimethyl-1h-indole-2-carbonyl)piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C12=CC=CC=C2NC(=O)N1C(CC1)CCN1C(=O)C1=CC2=CC(C)=CC(C)=C2N1 UBLULAQAHSJALJ-UHFFFAOYSA-N 0.000 description 1
SZZPNVNSBCOTGT-UHFFFAOYSA-N 3-[1-(5-bromo-1h-indole-2-carbonyl)piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C12=CC=CC=C2NC(=O)N1C(CC1)CCN1C(=O)C1=CC2=CC(Br)=CC=C2N1 SZZPNVNSBCOTGT-UHFFFAOYSA-N 0.000 description 1
ZWKMQTUMWXCFPI-UHFFFAOYSA-N 3-[1-(5-bromo-3-methyl-1h-indole-2-carbonyl)piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C12=CC=CC=C2NC(=O)N1C(CC1)CCN1C(=O)C1=C(C)C2=CC(Br)=CC=C2N1 ZWKMQTUMWXCFPI-UHFFFAOYSA-N 0.000 description 1
CTNXPMXFEUNVPA-UHFFFAOYSA-N 3-[1-(5-bromo-4-methyl-1h-indole-2-carbonyl)piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C12=CC=CC=C2NC(=O)N1C(CC1)CCN1C(=O)C(N1)=CC2=C1C=CC(Br)=C2C CTNXPMXFEUNVPA-UHFFFAOYSA-N 0.000 description 1
RFACBOUHRDRAHN-UHFFFAOYSA-N 3-[1-(5-chloro-1-methylindole-2-carbonyl)piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C12=CC=CC=C2NC(=O)N1C(CC1)CCN1C(=O)C1=CC2=CC(Cl)=CC=C2N1C RFACBOUHRDRAHN-UHFFFAOYSA-N 0.000 description 1
KUITXZGIOKXQGY-UHFFFAOYSA-N 3-[1-(5-chloro-1h-indole-2-carbonyl)piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C12=CC=CC=C2NC(=O)N1C(CC1)CCN1C(=O)C1=CC2=CC(Cl)=CC=C2N1 KUITXZGIOKXQGY-UHFFFAOYSA-N 0.000 description 1
IKDNYQQCXQPOGS-UHFFFAOYSA-N 3-[1-(5-chloro-4-methyl-1h-indole-2-carbonyl)piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C12=CC=CC=C2NC(=O)N1C(CC1)CCN1C(=O)C(N1)=CC2=C1C=CC(Cl)=C2C IKDNYQQCXQPOGS-UHFFFAOYSA-N 0.000 description 1
VGKVOBPKOUKJAO-UHFFFAOYSA-N 3-[1-(5-fluoro-1h-indole-2-carbonyl)piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C12=CC=CC=C2NC(=O)N1C(CC1)CCN1C(=O)C1=CC2=CC(F)=CC=C2N1 VGKVOBPKOUKJAO-UHFFFAOYSA-N 0.000 description 1
NVQHWZFUOMYOCY-UHFFFAOYSA-N 3-[1-(5-fluoro-4-methyl-1h-indole-2-carbonyl)piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C12=CC=CC=C2NC(=O)N1C(CC1)CCN1C(=O)C(N1)=CC2=C1C=CC(F)=C2C NVQHWZFUOMYOCY-UHFFFAOYSA-N 0.000 description 1
MWZDWGQFJGABMO-UHFFFAOYSA-N 3-[1-(5-methoxy-1h-indole-2-carbonyl)piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C12=CC=CC=C2NC(=O)N1C(CC1)CCN1C(=O)C1=CC2=CC(OC)=CC=C2N1 MWZDWGQFJGABMO-UHFFFAOYSA-N 0.000 description 1
FABPWIXCFHRPLK-UHFFFAOYSA-N 3-[1-(5-methoxy-6-methyl-1h-indole-2-carbonyl)piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C12=CC=CC=C2NC(=O)N1C(CC1)CCN1C(=O)C1=CC(C=C(C(=C2)C)OC)=C2N1 FABPWIXCFHRPLK-UHFFFAOYSA-N 0.000 description 1
KEAWEDZIKZBILI-UHFFFAOYSA-N 3-[1-(5-methyl-3-phenyl-1h-indole-2-carbonyl)piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C12=CC(C)=CC=C2NC(C(=O)N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)=C1C1=CC=CC=C1 KEAWEDZIKZBILI-UHFFFAOYSA-N 0.000 description 1
LSHWEXPQPBGCQK-UHFFFAOYSA-N 3-[1-(5h-[1,3]dioxolo[4,5-f]indole-6-carbonyl)piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1=C2NC(C(N3CCC(CC3)N3C(NC4=CC=CC=C43)=O)=O)=CC2=CC2=C1OCO2 LSHWEXPQPBGCQK-UHFFFAOYSA-N 0.000 description 1
BCEDKQSAJLXWOD-UHFFFAOYSA-N 3-[1-(6,7-dimethyl-1h-indole-2-carbonyl)piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C12=CC=CC=C2NC(=O)N1C(CC1)CCN1C(=O)C1=CC2=CC=C(C)C(C)=C2N1 BCEDKQSAJLXWOD-UHFFFAOYSA-N 0.000 description 1
NDGYGXBKUOGARM-UHFFFAOYSA-N 3-[1-(6-methoxy-1h-indole-2-carbonyl)piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C12=CC=CC=C2NC(=O)N1C(CC1)CCN1C(=O)C1=CC2=CC=C(OC)C=C2N1 NDGYGXBKUOGARM-UHFFFAOYSA-N 0.000 description 1
ZKRURXDSTSGXBO-UHFFFAOYSA-N 3-[1-(6-methoxy-3-methyl-1h-indole-2-carbonyl)piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C12=CC=CC=C2NC(=O)N1C(CC1)CCN1C(=O)C1=C(C)C2=CC=C(OC)C=C2N1 ZKRURXDSTSGXBO-UHFFFAOYSA-N 0.000 description 1
YPAKVTCANXPHCX-UHFFFAOYSA-N 3-benzyl-5-methyl-1h-indole-2-carboxylic acid Chemical compound C12=CC(C)=CC=C2NC(C(O)=O)=C1CC1=CC=CC=C1 YPAKVTCANXPHCX-UHFFFAOYSA-N 0.000 description 1
XOALTXJYIZPUCD-UHFFFAOYSA-N 3-ethyl-1h-indole-2-carboxylic acid Chemical compound C1=CC=C2C(CC)=C(C(O)=O)NC2=C1 XOALTXJYIZPUCD-UHFFFAOYSA-N 0.000 description 1
MXYFKDGEKGOGPL-UHFFFAOYSA-N 3-ethyl-4-methyl-1h-indole-2-carboxylic acid Chemical compound C1=CC(C)=C2C(CC)=C(C(O)=O)NC2=C1 MXYFKDGEKGOGPL-UHFFFAOYSA-N 0.000 description 1
PQEZZABTFGEOOL-UHFFFAOYSA-N 3-ethyl-5-methyl-1h-indole-2-carboxylic acid Chemical compound C1=C(C)C=C2C(CC)=C(C(O)=O)NC2=C1 PQEZZABTFGEOOL-UHFFFAOYSA-N 0.000 description 1
FEYRMXBCLPKSIJ-UHFFFAOYSA-N 3-phenyl-1h-indole-2-carboxylic acid Chemical compound OC(=O)C=1NC2=CC=CC=C2C=1C1=CC=CC=C1 FEYRMXBCLPKSIJ-UHFFFAOYSA-N 0.000 description 1
KFENNPMTTVJSET-UHFFFAOYSA-N 3h-1,3-benzoxazol-2-one;1h-indol-2-yl(piperidin-1-yl)methanone Chemical class C1=CC=C2OC(=O)NC2=C1.C=1C2=CC=CC=C2NC=1C(=O)N1CCCCC1 KFENNPMTTVJSET-UHFFFAOYSA-N 0.000 description 1
STMAOBOTFAMOLD-UHFFFAOYSA-N 4,5-dichloro-1h-indole-2-carboxylic acid Chemical compound ClC1=CC=C2NC(C(=O)O)=CC2=C1Cl STMAOBOTFAMOLD-UHFFFAOYSA-N 0.000 description 1
RNIQITJZXPDRHH-UHFFFAOYSA-N 4,5-dimethyl-1h-indole-2-carboxylic acid Chemical compound CC1=CC=C2NC(C(O)=O)=CC2=C1C RNIQITJZXPDRHH-UHFFFAOYSA-N 0.000 description 1
DXGLNXJHHJNUHD-UHFFFAOYSA-N 4,7-dimethyl-1h-indole-2-carboxylic acid Chemical compound CC1=CC=C(C)C2=C1C=C(C(O)=O)N2 DXGLNXJHHJNUHD-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
AXMULSMCSSBVRM-UHFFFAOYSA-N 4-chloro-5-methoxy-1h-indole-2-carboxylic acid Chemical compound COC1=CC=C2NC(C(O)=O)=CC2=C1Cl AXMULSMCSSBVRM-UHFFFAOYSA-N 0.000 description 1
229960000549 4-dimethylaminophenol Drugs 0.000 description 1
GYRFBSAMZLTZGJ-UHFFFAOYSA-N 4-ethyl-5-methyl-1h-indole-2-carboxylic acid Chemical compound CCC1=C(C)C=CC2=C1C=C(C(O)=O)N2 GYRFBSAMZLTZGJ-UHFFFAOYSA-N 0.000 description 1
OANDRQTUMDTTDU-UHFFFAOYSA-N 4-fluoro-n-[2-[4-(2-oxo-3h-benzimidazol-1-yl)piperidine-1-carbonyl]-1h-indol-3-yl]benzamide Chemical compound C1=CC(F)=CC=C1C(=O)NC1=C(C(=O)N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)NC2=CC=CC=C12 OANDRQTUMDTTDU-UHFFFAOYSA-N 0.000 description 1
POLWXRXLULAYBG-UHFFFAOYSA-N 4-fluoro-n-[5-methyl-2-[4-(2-oxo-3h-benzimidazol-1-yl)piperidine-1-carbonyl]-1h-indol-3-yl]benzamide Chemical compound C12=CC(C)=CC=C2NC(C(=O)N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)=C1NC(=O)C1=CC=C(F)C=C1 POLWXRXLULAYBG-UHFFFAOYSA-N 0.000 description 1
QMSCXKCJGFIXDF-UHFFFAOYSA-N 4-methyl-1h-indole-2-carboxylic acid Chemical compound CC1=CC=CC2=C1C=C(C(O)=O)N2 QMSCXKCJGFIXDF-UHFFFAOYSA-N 0.000 description 1
YMOJFBVIUIJKJS-UHFFFAOYSA-N 5,7-dimethyl-1h-indole-2-carboxylic acid Chemical compound CC1=CC(C)=C2NC(C(O)=O)=CC2=C1 YMOJFBVIUIJKJS-UHFFFAOYSA-N 0.000 description 1
SYYRSQYFVRJYCE-UHFFFAOYSA-N 5-bromo-1-(cyanomethyl)indole-2-carboxylic acid Chemical compound BrC1=CC=C2N(CC#N)C(C(=O)O)=CC2=C1 SYYRSQYFVRJYCE-UHFFFAOYSA-N 0.000 description 1
YAULOOYNCJDPPU-UHFFFAOYSA-N 5-bromo-1h-indole-2-carboxylic acid Chemical compound BrC1=CC=C2NC(C(=O)O)=CC2=C1 YAULOOYNCJDPPU-UHFFFAOYSA-N 0.000 description 1
TXEKYQYWSFKBJD-UHFFFAOYSA-N 5-bromo-4-methyl-1h-indole-2-carboxylic acid Chemical compound CC1=C(Br)C=CC2=C1C=C(C(O)=O)N2 TXEKYQYWSFKBJD-UHFFFAOYSA-N 0.000 description 1
BYQGBAGCNODQSS-UHFFFAOYSA-N 5-chloro-1-(cyanomethyl)indole-2-carboxylic acid Chemical compound ClC1=CC=C2N(CC#N)C(C(=O)O)=CC2=C1 BYQGBAGCNODQSS-UHFFFAOYSA-N 0.000 description 1
UTJVSPKRDDKHND-UHFFFAOYSA-N 5-chloro-1-methylindole-2-carboxylic acid Chemical compound ClC1=CC=C2N(C)C(C(O)=O)=CC2=C1 UTJVSPKRDDKHND-UHFFFAOYSA-N 0.000 description 1
FHGPOPGCRIYJLE-UHFFFAOYSA-N 5-chloro-4-methyl-1h-indole-2-carboxylic acid Chemical compound CC1=C(Cl)C=CC2=C1C=C(C(O)=O)N2 FHGPOPGCRIYJLE-UHFFFAOYSA-N 0.000 description 1
IVONMMGAULBXMQ-UHFFFAOYSA-N 5-chloro-7-methyl-1h-indole Chemical compound CC1=CC(Cl)=CC2=C1NC=C2 IVONMMGAULBXMQ-UHFFFAOYSA-N 0.000 description 1
GCUDEYKQAGCNBO-UHFFFAOYSA-N 5-chloro-7-methylindole-1,2-dicarboxylic acid Chemical compound CC1=CC(Cl)=CC2=C1N(C(O)=O)C(C(O)=O)=C2 GCUDEYKQAGCNBO-UHFFFAOYSA-N 0.000 description 1
VYRUSCDHMAEATM-UHFFFAOYSA-N 5-fluoro-4-methyl-1h-indole-2-carboxylic acid Chemical compound CC1=C(F)C=CC2=C1C=C(C(O)=O)N2 VYRUSCDHMAEATM-UHFFFAOYSA-N 0.000 description 1
ODFFPRGJZRXNHZ-UHFFFAOYSA-N 5-fluoroindole Chemical compound FC1=CC=C2NC=CC2=C1 ODFFPRGJZRXNHZ-UHFFFAOYSA-N 0.000 description 1
XECGSLQHGQQEJV-UHFFFAOYSA-N 5-methoxy-6-methyl-1h-indole-2-carboxylic acid Chemical compound C1=C(C)C(OC)=CC2=C1NC(C(O)=O)=C2 XECGSLQHGQQEJV-UHFFFAOYSA-N 0.000 description 1
RXFTYAQFRROLFJ-UHFFFAOYSA-N 5-methyl-3-phenyl-1h-indole-2-carboxylic acid Chemical compound C12=CC(C)=CC=C2NC(C(O)=O)=C1C1=CC=CC=C1 RXFTYAQFRROLFJ-UHFFFAOYSA-N 0.000 description 1
BJRAHWGTBUCWCY-UHFFFAOYSA-N 5h-[1,3]dioxolo[4,5-f]indole-6-carboxylic acid Chemical compound C1=C2NC(C(=O)O)=CC2=CC2=C1OCO2 BJRAHWGTBUCWCY-UHFFFAOYSA-N 0.000 description 1
UYOAURXJFUQILR-UHFFFAOYSA-N 6,7-dimethyl-1h-indole-2-carboxylic acid Chemical compound CC1=CC=C2C=C(C(O)=O)NC2=C1C UYOAURXJFUQILR-UHFFFAOYSA-N 0.000 description 1
XNBGANWAZJWOHS-UHFFFAOYSA-N 6-methoxy-1h-indole-2-carboxylic acid Chemical compound COC1=CC=C2C=C(C(O)=O)NC2=C1 XNBGANWAZJWOHS-UHFFFAOYSA-N 0.000 description 1
GAXRKJWZFDHHJC-UHFFFAOYSA-N 6-methoxy-3-methyl-1h-indole-2-carboxylic acid Chemical compound COC1=CC=C2C(C)=C(C(O)=O)NC2=C1 GAXRKJWZFDHHJC-UHFFFAOYSA-N 0.000 description 1
GLIJNMQVJMTMPC-UHFFFAOYSA-N 7-(bromomethyl)-1h-indole Chemical class BrCC1=CC=CC2=C1NC=C2 GLIJNMQVJMTMPC-UHFFFAOYSA-N 0.000 description 1
MUKNVPMLFAHORL-UHFFFAOYSA-N 7-phenylmethoxy-1h-indole-2-carboxylic acid Chemical compound C=12NC(C(=O)O)=CC2=CC=CC=1OCC1=CC=CC=C1 MUKNVPMLFAHORL-UHFFFAOYSA-N 0.000 description 1
239000004342 Benzoyl peroxide Substances 0.000 description 1
OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
238000009010 Bradford assay Methods 0.000 description 1
125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
XXRCUYVCPSWGCC-UHFFFAOYSA-N Ethyl pyruvate Chemical compound CCOC(=O)C(C)=O XXRCUYVCPSWGCC-UHFFFAOYSA-N 0.000 description 1
238000006783 Fischer indole synthesis reaction Methods 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
206010062767 Hypophysitis Diseases 0.000 description 1
229910013596 LiOH—H2O Inorganic materials 0.000 description 1
235000019759 Maize starch Nutrition 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
206010030302 Oliguria Diseases 0.000 description 1
BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
229910000831 Steel Inorganic materials 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
101710120037 Toxin CcdB Proteins 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
206010047139 Vasoconstriction Diseases 0.000 description 1
DXGTUUQHTDOFFQ-UHFFFAOYSA-N [N].C1=CC=C2NC=CC2=C1 Chemical compound [N].C1=CC=C2NC=CC2=C1 DXGTUUQHTDOFFQ-UHFFFAOYSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
230000002686 anti-diuretic effect Effects 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
229940124572 antihypotensive agent Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
239000000074 antisense oligonucleotide Substances 0.000 description 1
238000012230 antisense oligonucleotides Methods 0.000 description 1
230000010397 anxiety-related behavior Effects 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
235000019400 benzoyl peroxide Nutrition 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
230000031709 bromination Effects 0.000 description 1
238000005893 bromination reaction Methods 0.000 description 1
239000000872 buffer Substances 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
125000004966 cyanoalkyl group Chemical group 0.000 description 1
230000006735 deficit Effects 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
ZFTFAPZRGNKQPU-UHFFFAOYSA-N dicarbonic acid Chemical compound OC(=O)OC(O)=O ZFTFAPZRGNKQPU-UHFFFAOYSA-N 0.000 description 1
125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
201000010099 disease Diseases 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
150000002148 esters Chemical group 0.000 description 1
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
BORDUBSKEZATIX-UHFFFAOYSA-N ethyl 1-(cyanomethyl)indole-2-carboxylate Chemical compound C1=CC=C2N(CC#N)C(C(=O)OCC)=CC2=C1 BORDUBSKEZATIX-UHFFFAOYSA-N 0.000 description 1
RPUBQHHTWCDTAO-UHFFFAOYSA-N ethyl 2-[(4-chloro-2-methylphenyl)hydrazinylidene]propanoate Chemical compound CCOC(=O)C(C)=NNC1=CC=C(Cl)C=C1C RPUBQHHTWCDTAO-UHFFFAOYSA-N 0.000 description 1
QLIWTTDJWICLBL-UHFFFAOYSA-N ethyl 2-[2-[4-(2-oxo-3h-benzimidazol-1-yl)piperidine-1-carbonyl]-1h-indol-3-yl]acetate Chemical compound C12=CC=CC=C2NC(=O)N1C(CC1)CCN1C(=O)C1=C(CC(=O)OCC)C2=CC=CC=C2N1 QLIWTTDJWICLBL-UHFFFAOYSA-N 0.000 description 1
KKRALFOTPOOJLZ-UHFFFAOYSA-N ethyl 5-bromo-1-(cyanomethyl)indole-2-carboxylate Chemical compound BrC1=CC=C2N(CC#N)C(C(=O)OCC)=CC2=C1 KKRALFOTPOOJLZ-UHFFFAOYSA-N 0.000 description 1
HMHXBFQJBLYGQF-UHFFFAOYSA-N ethyl 5-chloro-1-(cyanomethyl)indole-2-carboxylate Chemical compound ClC1=CC=C2N(CC#N)C(C(=O)OCC)=CC2=C1 HMHXBFQJBLYGQF-UHFFFAOYSA-N 0.000 description 1
229940117360 ethyl pyruvate Drugs 0.000 description 1
230000029142 excretion Effects 0.000 description 1
239000011888 foil Substances 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
230000004116 glycogenolysis Effects 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
230000000004 hemodynamic effect Effects 0.000 description 1
210000001320 hippocampus Anatomy 0.000 description 1
210000003016 hypothalamus Anatomy 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
125000000593 indol-1-yl group Chemical group [H]C1=C([H])C([H])=C2N([*])C([H])=C([H])C2=C1[H] 0.000 description 1
150000002475 indoles Chemical class 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000008011 inorganic excipient Substances 0.000 description 1
229960004903 invert sugar Drugs 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
OCVXZQOKBHXGRU-UHFFFAOYSA-N iodine(1+) Chemical compound [I+] OCVXZQOKBHXGRU-UHFFFAOYSA-N 0.000 description 1
CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
230000002197 limbic effect Effects 0.000 description 1
GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
230000000873 masking effect Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000002156 mixing Methods 0.000 description 1
125000002757 morpholinyl group Chemical group 0.000 description 1
210000002464 muscle smooth vascular Anatomy 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
HOHOVELMLJBYAW-UHFFFAOYSA-N n-[1-[2-[4-(2-oxo-3h-benzimidazol-1-yl)piperidine-1-carbonyl]-1h-indol-3-yl]propan-2-yl]acetamide Chemical compound C12=CC=CC=C2NC(=O)N1C(CC1)CCN1C(=O)C1=C(CC(C)NC(C)=O)C2=CC=CC=C2N1 HOHOVELMLJBYAW-UHFFFAOYSA-N 0.000 description 1
YITLYYNHNYRRPL-UHFFFAOYSA-N n-[2-[5-methoxy-7-nitro-2-[4-(2-oxo-3h-benzimidazol-1-yl)piperidine-1-carbonyl]-1h-indol-3-yl]ethyl]acetamide Chemical compound C12=CC=CC=C2NC(=O)N1C(CC1)CCN1C(=O)C1=C(CCNC(C)=O)C2=CC(OC)=CC([N+]([O-])=O)=C2N1 YITLYYNHNYRRPL-UHFFFAOYSA-N 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000011224 negative regulation of urine volume Effects 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
238000010534 nucleophilic substitution reaction Methods 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
229940046166 oligodeoxynucleotide Drugs 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
239000008012 organic excipient Substances 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
210000002963 paraventricular hypothalamic nucleus Anatomy 0.000 description 1
125000002409 penten-3-yl group Chemical group C=CC(CC)* 0.000 description 1
125000002262 penten-4-yl group Chemical group C=CCC(C)* 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
125000003386 piperidinyl group Chemical group 0.000 description 1
210000003635 pituitary gland Anatomy 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
238000000746 purification Methods 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
125000000719 pyrrolidinyl group Chemical group 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
238000010992 reflux Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
125000006413 ring segment Chemical group 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 1
210000001679 solitary nucleus Anatomy 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000010959 steel Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
230000009182 swimming Effects 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
125000003944 tolyl group Chemical group 0.000 description 1
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
230000025102 vascular smooth muscle contraction Effects 0.000 description 1
230000025033 vasoconstriction Effects 0.000 description 1
239000005526 vasoconstrictor agent Substances 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Urology & Nephrology (AREA)
Reproductive Health (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

BRPI0720441-8A 2006-12-08 2007-11-29 Indóis que atuam como antagonistas de receptor v1a BRPI0720441A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP06125663.2		2006-12-08
EP06125663		2006-12-08
PCT/EP2007/062984 WO2008068184A1 (en)	2006-12-08	2007-11-29	Indoles which act as via receptor antagonists

Publications (1)

Publication Number	Publication Date
BRPI0720441A2 true BRPI0720441A2 (pt)	2014-01-07

Family

ID=38983746

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0720441-8A BRPI0720441A2 (pt)	2006-12-08	2007-11-29	Indóis que atuam como antagonistas de receptor v1a

Country Status (21)

Country	Link
US (4)	US20080139617A1 (de)
EP (1)	EP2089381B1 (de)
JP (1)	JP2010511660A (de)
KR (1)	KR101050558B1 (de)
CN (1)	CN101541786A (de)
AR (1)	AR064137A1 (de)
AT (1)	ATE472544T1 (de)
AU (1)	AU2007328994B2 (de)
BR (1)	BRPI0720441A2 (de)
CA (1)	CA2671324A1 (de)
CL (1)	CL2007003503A1 (de)
DE (1)	DE602007007512D1 (de)
ES (1)	ES2345132T3 (de)
IL (1)	IL198683A0 (de)
MX (1)	MX2009005541A (de)
NO (1)	NO20091832L (de)
PE (1)	PE20081380A1 (de)
RU (1)	RU2009120443A (de)
TW (1)	TW200829570A (de)
WO (1)	WO2008068184A1 (de)
ZA (1)	ZA200903499B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR101050558B1 (ko) *	2006-12-08	2011-07-19	에프. 호프만-라 로슈 아게	Ｖ1ａ 수용체 길항제로서 작용하는 인돌
MX2009005544A (es) *	2006-12-08	2009-06-05	Hoffmann La Roche	Indoles.
PE20081401A1 (es)	2006-12-28	2008-10-24	Hoffmann La Roche	Derivados de indol como antagonistas de receptores vasopresina
US20100145805A1 (en) *	2008-12-08	2010-06-10	Electronics And Telecommunications Research Institute	Apparatus for providing digital contents using dmb channel and method thereof
US20150376198A1 (en) *	2013-02-18	2015-12-31	The Scripps Research Institute	Modulators of vasopressin receptors with therapeutic potential
GB201521059D0 (en)	2015-11-30	2016-01-13	Isis Innovation	Inhibitors of metallo-beta-lactamases
WO2020216378A1 (zh) *	2019-04-26	2020-10-29	健艾仕生物医药有限公司	一种含杂环的化合物、其应用及含其的组合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5924990B2 (ja) *	1979-11-21	1984-06-13	協和醗酵工業株式会社	新規なピペリジン誘導体
TW199153B (de) *	1990-08-07	1993-02-01	Dtsuka Seiyaku Kk
AU691829B2 (en) *	1993-07-16	1998-05-28	Merck & Co., Inc.	Benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytocin receptor antagonists
CO5150201A1 (es)	1998-09-07	2002-04-29	Hoffmann La Roche	Derivados de piperidina
AU6392701A (en)	2000-05-12	2001-11-20	Solvay Pharm Bv	Piperazine and piperidine compounds
JP2006505570A (ja)	2002-10-17	2006-02-16	アムジエン・インコーポレーテツド	ベンズイミダゾール誘導体およびそれのバニロイド受容体リガンドとしての使用
AU2006268724B2 (en) *	2005-07-14	2011-06-02	F. Hoffmann-La Roche Ag	Indol-3-carbonyl-spiro-piperidine derivatives as V1A receptor antagonists
PL1912976T3 (pl) *	2005-07-21	2009-04-30	Hoffmann La Roche	Pochodne indol-3-ilokarbonylopiperydynobenzoimidazolu jako antagoniści receptora V1a
ATE488519T1 (de) *	2005-09-28	2010-12-15	Hoffmann La Roche	Indol-3-ylcarbonylazaspiroderivate als vasopressinrezeptorantagonisten
KR101050558B1 (ko) *	2006-12-08	2011-07-19	에프. 호프만-라 로슈 아게	Ｖ1ａ 수용체 길항제로서 작용하는 인돌

2007
- 2007-11-29 KR KR1020097011629A patent/KR101050558B1/ko not_active Expired - Fee Related
- 2007-11-29 ES ES07847501T patent/ES2345132T3/es active Active
- 2007-11-29 RU RU2009120443/04A patent/RU2009120443A/ru not_active Application Discontinuation
- 2007-11-29 EP EP07847501A patent/EP2089381B1/de not_active Not-in-force
- 2007-11-29 DE DE602007007512T patent/DE602007007512D1/de active Active
- 2007-11-29 US US11/947,266 patent/US20080139617A1/en not_active Abandoned
- 2007-11-29 US US11/998,371 patent/US7799923B2/en not_active Expired - Fee Related
- 2007-11-29 AU AU2007328994A patent/AU2007328994B2/en not_active Ceased
- 2007-11-29 US US11/947,146 patent/US8071622B2/en not_active Expired - Fee Related
- 2007-11-29 CA CA002671324A patent/CA2671324A1/en not_active Abandoned
- 2007-11-29 BR BRPI0720441-8A patent/BRPI0720441A2/pt not_active IP Right Cessation
- 2007-11-29 MX MX2009005541A patent/MX2009005541A/es active IP Right Grant
- 2007-11-29 JP JP2009539706A patent/JP2010511660A/ja active Pending
- 2007-11-29 US US11/947,195 patent/US20080139618A1/en not_active Abandoned
- 2007-11-29 WO PCT/EP2007/062984 patent/WO2008068184A1/en not_active Ceased
- 2007-11-29 CN CNA2007800421348A patent/CN101541786A/zh active Pending
- 2007-11-29 AT AT07847501T patent/ATE472544T1/de active
- 2007-12-05 CL CL200703503A patent/CL2007003503A1/es unknown
- 2007-12-05 AR ARP070105428A patent/AR064137A1/es unknown
- 2007-12-06 TW TW096146544A patent/TW200829570A/zh unknown
- 2007-12-07 PE PE2007001745A patent/PE20081380A1/es not_active Application Discontinuation
2009
- 2009-05-11 IL IL198683A patent/IL198683A0/en unknown
- 2009-05-11 NO NO20091832A patent/NO20091832L/no not_active Application Discontinuation
- 2009-05-20 ZA ZA200903499A patent/ZA200903499B/xx unknown

Also Published As

Publication number	Publication date
AU2007328994A1 (en)	2008-06-12
US20080139618A1 (en)	2008-06-12
AR064137A1 (es)	2009-03-18
MX2009005541A (es)	2009-06-05
EP2089381B1 (de)	2010-06-30
IL198683A0 (en)	2010-02-17
US7799923B2 (en)	2010-09-21
CN101541786A (zh)	2009-09-23
US20080139548A1 (en)	2008-06-12
DE602007007512D1 (de)	2010-08-12
TW200829570A (en)	2008-07-16
WO2008068184A1 (en)	2008-06-12
US20080269290A1 (en)	2008-10-30
EP2089381A1 (de)	2009-08-19
ZA200903499B (en)	2010-03-31
US20080139617A1 (en)	2008-06-12
NO20091832L (no)	2009-07-07
KR20090078368A (ko)	2009-07-17
CA2671324A1 (en)	2008-06-12
ATE472544T1 (de)	2010-07-15
KR101050558B1 (ko)	2011-07-19
ES2345132T3 (es)	2010-09-15
CL2007003503A1 (es)	2008-07-04
PE20081380A1 (es)	2008-09-18
JP2010511660A (ja)	2010-04-15
AU2007328994B2 (en)	2012-03-08
RU2009120443A (ru)	2011-01-20
US8071622B2 (en)	2011-12-06

Legal Events

Date	Code	Title	Description
2014-08-26	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 6A ANUIDADE.
2014-12-16	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2277 DE 26/08/2014.

Publication	Publication Date	Title
BRPI0620951A2 (pt)	2011-11-29	derivados de indol-3-il-carbonil-espiro-piperidina
BRPI0720246A2 (pt)	2013-12-31	Derivados de espiro-piperidina
ES2345132T3 (es)	2010-09-15	Indoles que actuan como agonistas del receptor v1a.
ES2371784T3 (es)	2012-01-10	Indoles.
IL188722A (en)	2012-12-31	Indol-3-yl-carbonyl-piperidin-benzoimidazol derivatives as v1a
BRPI0720004A2 (pt)	2013-12-17	Derivados de espiro-piperidina como antagonista de receptor v1a
ES2375520T3 (es)	2012-03-01	Derivados de indol-3-il-carbonil-piperidina para el tratamiento de ansiedad y trastornos depresivos por antagonismo del receptor de la v1a.